{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:07:06Z","timestamp":1793830026774,"version":"4.6.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T00:00:00Z","timestamp":1710633600000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Androgen deprivation therapy (ADT) is widely used for the treatment of prostate cancer. ADT is associated with reduced bone density leading to an increased risk of osteoporotic fracture. The objective of this retrospective cohort study was to quantify fracture risk in men treated with ADT for prostate cancer in real-world practice in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Data were extracted from the Japanese Medical Data Vision (MDV) database. Men initiating ADT for treatment of prostate cancer between April 2010 and March 2021 were identified and matched to a cohort of prostate cancer patients not taking ADT using a propensity score. Fracture rates were estimated by a cumulative incidence function and compared between cohorts using a Cox cause-specific hazard model. Information was extracted on demographics, comorbidities and bone densitometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>30,561 men with PC starting ADT were matched to 30,561 men with prostate cancer not treated with ADT. Following ADT initiation, &lt;5% of men underwent bone densitometry. Prescription of ADT was associated with an increased fracture risk compared to not taking ADT (adjusted hazard ratio: 1.63 [95% CI 1.52\u20131.75]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ADT is associated with a 1.6-fold increase in the risk of osteoporotic fracture in men with prostate cancer. Densitometry in this population is infrequent and monitoring urgently needs to be improved in order to implement effective fracture prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00774-024-01497-4","type":"journal-article","created":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T10:01:37Z","timestamp":1710669697000},"page":"223-232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2567-8008","authenticated-orcid":false,"given":"Hisashi","family":"Matsushima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Jab\u0142o\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,17]]},"reference":[{"key":"1497_CR1","doi-asserted-by":"publisher","first-page":"811044","DOI":"10.3389\/fpubh.2022.811044","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, Lu B, He M, Wang Y, Wang Z, Du L (2022) Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health 10:811044. https:\/\/doi.org\/10.3389\/fpubh.2022.811044","journal-title":"Front Public Health"},{"key":"1497_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/genes13061039","author":"GM Vieira","year":"2022","unstructured":"Vieira GM, Gellen LPA, da Veiga Borges Leal DF, Pastana LF, Vinagre L, Aquino VT, Fernandes MR, de Assump\u00e7\u00e3o PP, Burbano RMR, Dos Santos SEB, Dos Santos NPC (2022) Correlation between Genomic Variants and Worldwide Epidemiology of Prostate Cancer. Genes (Basel). https:\/\/doi.org\/10.3390\/genes13061039","journal-title":"Genes (Basel)"},{"key":"1497_CR3","doi-asserted-by":"publisher","first-page":"5653862","DOI":"10.1155\/2016\/5653862","volume":"2016","author":"MM Kgatle","year":"2016","unstructured":"Kgatle MM, Kalla AA, Islam MM, Sathekge M, Moorad R (2016) Prostate cancer: epigenetic alterations, risk factors, and therapy. Prostate Cancer 2016:5653862. https:\/\/doi.org\/10.1155\/2016\/5653862","journal-title":"Prostate Cancer"},{"key":"1497_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG (2021) Prostate cancer. Nat Rev Dis Primers 7:9. https:\/\/doi.org\/10.1038\/s41572-020-00243-0","journal-title":"Nat Rev Dis Primers"},{"key":"1497_CR5","doi-asserted-by":"publisher","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, et al.  (2023) Prostate Cancer, Version 4 (2023) NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 21:1067\u20131096. https:\/\/doi.org\/10.6004\/jnccn.2023.0050","DOI":"10.6004\/jnccn.2023.0050"},{"key":"1497_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1152\/physrev.00033.2015","volume":"97","author":"M Almeida","year":"2017","unstructured":"Almeida M, Laurent MR, Dubois V, Claessens F, O\u2019Brien CA, Bouillon R, Vanderschueren D, Manolagas SC (2017) Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev 97:135\u2013187. https:\/\/doi.org\/10.1152\/physrev.00033.2015","journal-title":"Physiol Rev"},{"key":"1497_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41391-020-00296-y","volume":"24","author":"A Hussain","year":"2021","unstructured":"Hussain A, Tripathi A, Pieczonka C, Cope D, McNatty A, Logothetis C, Guise T (2021) Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 24:290\u2013300. https:\/\/doi.org\/10.1038\/s41391-020-00296-y","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1497_CR8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2147\/cia.s115472","volume":"11","author":"NV Mohamad","year":"2016","unstructured":"Mohamad NV, Soelaiman IN, Chin KY (2016) A concise review of testosterone and bone health. Clin Interv Aging 11:1317\u20131324. https:\/\/doi.org\/10.2147\/cia.s115472","journal-title":"Clin Interv Aging"},{"key":"1497_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/s2213-8587(18)30047-0","volume":"6","author":"TD Rachner","year":"2018","unstructured":"Rachner TD, Coleman R, Hadji P, Hofbauer LC (2018) Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol 6:901\u2013910. https:\/\/doi.org\/10.1016\/s2213-8587(18)30047-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1497_CR10","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s00198-013-2343-4","volume":"24","author":"SM Alibhai","year":"2013","unstructured":"Alibhai SM, Mohamedali HZ, Gulamhusein H, Panju AH, Breunis H, Timilshina N, Fleshner N, Krahn MD, Naglie G, Tannock IF, Tomlinson G, Warde P, Duff Canning S, Cheung AM (2013) Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. Osteoporos Int 24:2571\u20132579. https:\/\/doi.org\/10.1007\/s00198-013-2343-4","journal-title":"Osteoporos Int"},{"key":"1497_CR11","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410\u20136417. https:\/\/doi.org\/10.1210\/jc.2005-0183","journal-title":"J Clin Endocrinol Metab"},{"key":"1497_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12020-013-0083-z","volume":"45","author":"AC Lassemillante","year":"2014","unstructured":"Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR (2014) Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine 45:370\u2013381. https:\/\/doi.org\/10.1007\/s12020-013-0083-z","journal-title":"Endocrine"},{"key":"1497_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1186\/s12885-015-1843-3","volume":"15","author":"A Wang","year":"2015","unstructured":"Wang A, Obertov\u00e1 Z, Brown C, Karunasinghe N, Bishop K, Ferguson L, Lawrenson R (2015) Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer 15:837. https:\/\/doi.org\/10.1186\/s12885-015-1843-3","journal-title":"BMC Cancer"},{"key":"1497_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154\u2013164. https:\/\/doi.org\/10.1056\/NEJMoa041943","journal-title":"N Engl J Med"},{"key":"1497_CR15","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1007\/s00198-015-3135-9","volume":"26","author":"CT Wu","year":"2015","unstructured":"Wu CT, Yang YH, Chen PC, Chen MF, Chen WC (2015) Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. Osteoporos Int 26:2281\u20132290. https:\/\/doi.org\/10.1007\/s00198-015-3135-9","journal-title":"Osteoporos Int"},{"key":"1497_CR16","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.ejca.2012.01.035","volume":"48","author":"A Thorstenson","year":"2012","unstructured":"Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, Lambe M, Bill-Axelson A, Stattin P, Adolfsson J (2012) Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer 48:1672\u20131681. https:\/\/doi.org\/10.1016\/j.ejca.2012.01.035","journal-title":"Eur J Cancer"},{"key":"1497_CR17","doi-asserted-by":"publisher","first-page":"e74492","DOI":"10.1371\/journal.pone.0074492","volume":"8","author":"M Van Hemelrijck","year":"2013","unstructured":"Van Hemelrijck M, Garmo H, Micha\u00eblsson K, Thorstenson A, Akre O, Stattin P, Holmberg L, Adolfsson J (2013) Mortality following hip fracture in men with prostate cancer. PLoS ONE 8:e74492. https:\/\/doi.org\/10.1371\/journal.pone.0074492","journal-title":"PLoS ONE"},{"key":"1497_CR18","doi-asserted-by":"publisher","first-page":"75646","DOI":"10.18632\/oncotarget.17980","volume":"8","author":"L Cianferotti","year":"2017","unstructured":"Cianferotti L, Bertoldo F, Carini M, Kanis JA, Lapini A, Longo N, Martorana G, Mirone V, Reginster JY, Rizzoli R, Brandi ML (2017) The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget 8:75646\u201375663. https:\/\/doi.org\/10.18632\/oncotarget.17980","journal-title":"Oncotarget"},{"key":"1497_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00774-020-01087-0","volume":"38","author":"S Fukumoto","year":"2020","unstructured":"Fukumoto S, Soen S, Taguchi T, Ishikawa T, Matsushima H, Terauchi M, Horie S, Yoneda T, Sugimoto T, Matsumoto T (2020) Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR. J Bone Miner Metab 38:141\u2013144. https:\/\/doi.org\/10.1007\/s00774-020-01087-0","journal-title":"J Bone Miner Metab"},{"key":"1497_CR20","unstructured":"Centre for Metabolic Bone Diseases at the University of Sheffield (UK) FRAX\u00aeFracture Risk Assessment Tool. https:\/\/www.sheffield.ac.uk\/FRAX\/. Accessed 1 July 2022"},{"key":"1497_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3820\/jjpe.21.23","volume":"21","author":"M Nakamura","year":"2016","unstructured":"Nakamura M (2016) 1. Utilization of MDV data and data quality control. Jpn J Pharmacoepidemiol 21:23\u201325. https:\/\/doi.org\/10.3820\/jjpe.21.23","journal-title":"Jpn J Pharmacoepidemiol"},{"key":"1497_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12874-020-00994-0","volume":"20","author":"E Granger","year":"2020","unstructured":"Granger E, Watkins T, Sergeant JC, Lunt M (2020) A review of the use of propensity score diagnostics in papers published in high-ranking medical journals. BMC Med Res Methodol 20:132. https:\/\/doi.org\/10.1186\/s12874-020-00994-0","journal-title":"BMC Med Res Methodol"},{"key":"1497_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2307\/2335942","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41\u201355. https:\/\/doi.org\/10.2307\/2335942","journal-title":"Biometrika"},{"key":"1497_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-sts313","volume":"25","author":"EA Stuart","year":"2010","unstructured":"Stuart EA (2010) Matching methods for causal inference: a review and a look forward. Stat Sci 25:1\u201321. https:\/\/doi.org\/10.1214\/09-sts313","journal-title":"Stat Sci"},{"key":"1497_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/circulationaha.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin PC, Lee DS, Fine JP (2016) Introduction to the analysis of survival data in the presence of competing risks. Circulation 133:601\u2013609. https:\/\/doi.org\/10.1161\/circulationaha.115.017719","journal-title":"Circulation"},{"key":"1497_CR26","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1093\/ndt\/gft355","volume":"28","author":"M Noordzij","year":"2013","unstructured":"Noordzij M, Leffondr\u00e9 K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ (2013) When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant 28:2670\u20132677. https:\/\/doi.org\/10.1093\/ndt\/gft355","journal-title":"Nephrol Dial Transplant"},{"key":"1497_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/bor.0000000000000789","volume":"33","author":"KD Wysham","year":"2021","unstructured":"Wysham KD, Baker JF, Shoback DM (2021) Osteoporosis and fractures in rheumatoid arthritis. Curr Opin Rheumatol 33:270\u2013276. https:\/\/doi.org\/10.1097\/bor.0000000000000789","journal-title":"Curr Opin Rheumatol"},{"key":"1497_CR28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00198-009-0961-7","volume":"21","author":"P Trimpou","year":"2010","unstructured":"Trimpou P, Landin-Wilhelmsen K, Od\u00e9n A, Rosengren A, Wilhelmsen L (2010) Male risk factors for hip fracture-a 30-year follow-up study in 7,495 men. Osteoporos Int 21:409\u2013416. https:\/\/doi.org\/10.1007\/s00198-009-0961-7","journal-title":"Osteoporos Int"},{"key":"1497_CR29","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/cncr.24283","volume":"115","author":"LG Taylor","year":"2009","unstructured":"Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115:2388\u20132399. https:\/\/doi.org\/10.1002\/cncr.24283","journal-title":"Cancer"},{"key":"1497_CR30","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00774-021-01236-z","volume":"39","author":"S Soen","year":"2021","unstructured":"Soen S, Kaku M, Okubo N, Touzeni S, Saito K, Kobayashi M (2021) Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan. J Bone Miner Metab 39:1019\u20131030. https:\/\/doi.org\/10.1007\/s00774-021-01236-z","journal-title":"J Bone Miner Metab"},{"key":"1497_CR31","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMcp0707217","volume":"358","author":"PR Ebeling","year":"2008","unstructured":"Ebeling PR (2008) Clinical practice. Osteoporosis in men. N Engl J Med 358:1474\u20131482. https:\/\/doi.org\/10.1056\/NEJMcp0707217","journal-title":"N Engl J Med"},{"key":"1497_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.afos.2019.09.003","volume":"5","author":"H Hagino","year":"2019","unstructured":"Hagino H, Wada T (2019) Osteoporosis liaison service in Japan. Osteoporos Sarcopenia 5:65\u201368. https:\/\/doi.org\/10.1016\/j.afos.2019.09.003","journal-title":"Osteoporos Sarcopenia"},{"key":"1497_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/s0167-4943(99)00034-5","volume":"29","author":"A Johansen","year":"1999","unstructured":"Johansen A, Harding K, Evans R, Stone M (1999) Trauma in elderly people: what proportion of fractures are a consequence of bone fragility? Arch Gerontol Geriatr 29:215\u2013221. https:\/\/doi.org\/10.1016\/s0167-4943(99)00034-5","journal-title":"Arch Gerontol Geriatr"},{"key":"1497_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0020-1383(95)93500-h","volume":"26","author":"A Nather","year":"1995","unstructured":"Nather A, Seow CS, Iau P, Chan A (1995) Morbidity and mortality for elderly patients with fractured neck of femur treated by hemiarthroplasty. Injury 26:187\u2013190. https:\/\/doi.org\/10.1016\/0020-1383(95)93500-h","journal-title":"Injury"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-024-01497-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-024-01497-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-024-01497-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T03:02:18Z","timestamp":1711854138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-024-01497-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1497"],"URL":"https:\/\/doi.org\/10.1007\/s00774-024-01497-4","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HM has received consulting fees, speaking fees or honoraria from Daiichi Sankyo Co., Ltd. TT has received consulting fees from Daiichi Sankyo Co., Ltd., speaking fees from Pfizer and Asahi Kasei Pharma Corporation. SF has received consulting fees, speaking fees or honoraria from Daiichi Sankyo Co., Ltd. TM has received consulting fees, speaking fees or honoraria from Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. SK and NO and KS are employees of Daiichi Sankyo Co., Ltd., a pharmaceutical company which markets medications for the treatment of osteoporosis. KJ is an employee of Putnam PHMR, a consultancy company who received funding from Daiichi Sankyo Co., Ltd. for the implementation of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}